MPS Pharmaa Past Earnings Performance

Past criteria checks 0/6

MPS Pharmaa has been growing earnings at an average annual rate of 21.8%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 9.4% per year.

Key information

21.8%

Earnings growth rate

21.8%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate9.4%
Return on equity-59.0%
Net Margin-14,174.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How MPS Pharmaa makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BSE:531686 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-950
30 Jun 241-950
31 Mar 241-850
31 Dec 231-950
30 Sep 231-950
30 Jun 231-1050
31 Mar 230-1150
31 Dec 220-350
30 Sep 220-350
30 Jun 220-140
31 Mar 220-140
31 Dec 213-7-300
30 Sep 213-4240
30 Jun 212-44390
31 Mar 210-4440
31 Dec 200-46390
30 Sep 200-1140
30 Jun 200-1240
31 Mar 200-1250
31 Dec 190-1150
30 Sep 190-1250
30 Jun 199-1250
31 Mar 198-1250
31 Dec 189-1160
30 Sep 1821-1160
30 Jun 1828-1060
31 Mar 1841-970
31 Dec 1746-3490
30 Sep 1744-3490
30 Jun 1737-35100
31 Mar 1729-74100
31 Dec 1632-4490
30 Sep 163-4690
30 Jun 16-3-4780
31 Mar 1614-12100
31 Dec 1519-21140
30 Sep 1567-17140
30 Jun 15109-13100
31 Mar 15122-7100
31 Dec 142123110
30 Sep 142635110
30 Jun 14253570
31 Mar 143035100

Quality Earnings: 531686 is currently unprofitable.

Growing Profit Margin: 531686 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 531686 is unprofitable, but has reduced losses over the past 5 years at a rate of 21.8% per year.

Accelerating Growth: Unable to compare 531686's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 531686 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (20.5%).


Return on Equity

High ROE: 531686 has a negative Return on Equity (-59.01%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 00:22
End of Day Share Price 2025/01/06 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MPS Pharmaa Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution